|
gptkbp:instanceOf
|
gptkb:drug
antidepressant
|
|
gptkbp:approvalYear
|
2002
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
N06AB10
|
|
gptkbp:availableOn
|
gptkb:tablet
oral solution
|
|
gptkbp:brand
|
gptkb:Lexapro
gptkb:Cipralex
gptkb:Seroplex
|
|
gptkbp:CASNumber
|
128196-01-0
|
|
gptkbp:chemicalFormula
|
C20H21FN2O
|
|
gptkbp:contraindication
|
concomitant use with MAO inhibitors
|
|
gptkbp:developedBy
|
gptkb:Lundbeck
|
|
gptkbp:drugClass
|
selective serotonin reuptake inhibitor
|
|
gptkbp:eliminationHalfLife
|
27–32 hours
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:genericName
|
gptkb:escitalopram
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Lexapro
|
|
gptkbp:lactationWarning
|
caution advised
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:manufacturer
|
gptkb:Forest_Laboratories
|
|
gptkbp:marketedIn
|
gptkb:Australia
gptkb:Canada
gptkb:Europe
gptkb:Japan
gptkb:United_States
|
|
gptkbp:mechanismOfAction
|
inhibits reuptake of serotonin
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:overdoseSymptoms
|
dizziness
tremor
agitation
convulsions
|
|
gptkbp:patentExpired
|
2012 (US)
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:pregnancyWarning
|
use only if clearly needed
|
|
gptkbp:prescribes
|
adults
adolescents (in some countries)
|
|
gptkbp:prescriptionStatus
|
Rx only
|
|
gptkbp:relatedTo
|
gptkb:citalopram
|
|
gptkbp:riskFactor
|
gptkb:serotonin_syndrome
QT prolongation
suicidal thoughts in young adults
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
insomnia
dry mouth
sexual dysfunction
increased sweating
|
|
gptkbp:usedFor
|
gptkb:generalized_anxiety_disorder
gptkb:major_depressive_disorder
|
|
gptkbp:bfsParent
|
gptkb:escitalopram
gptkb:Forest_Laboratories
gptkb:Escitalopram
gptkb:Selective_serotonin_reuptake_inhibitors
|
|
gptkbp:bfsLayer
|
7
|